In 2025, the biotech, drug discovery, and medical device sectors have experienced notably low IPO activity, with only 16 funded U.S. startups debuting on Nasdaq or the New York Stock Exchange, according to Crunchbase data. This marks one of the slowest years for biotech IPOs in recent times.
The American Customer Satisfaction Index read 76.1 in August 2026, the same score it held in 2015, so United States customer expectations have held flat for eleven years while complaints hit records and the variable that actually moved was tolerance.
Read More
TLDR: Regulated-industry marketers who build neuromarketing capabilities at pre-launch stage convert compliance...
Read More